Depomed and Esprit end ProQuin XR deal
California, USA-based specialty pharmaceutical firm Depomed says that it has ended its license and co-promotion agreement with fellow US company Esprit Pharma, under which the two firms were selling ProQuin XR, a once-daily, extended-release formulation of the antibiotic ciprofloxacin, for the treatment of uncomplicated urinary tract infections.
Under the terms of the termination agreement, Esprit has paid Depomed $17.5 million and will also return ownership of the ProQuin New Drug Application and all promotional materials. The firms have also set in motion a detailed transition plan with specific responsibilities and timelines related to the transfer of the product over the next few months. Depomed said that it would utilize the distribution network it has established for its once-daily diabetes mellitus drug Glumetza to sell ProQuin in the USA.
Depomed chairman John Fara said that the firm was pleased with the arrangement, and added that it continues to believe in the product and is in ongoing discussions with other potential new partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze